- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07920484
A Clinical Study to Collect Real-wordt Data on Safety and Clinical Performance of the VCFix Spinal System for Treatment of Vertebral Compression Fractures of (Suspected) Osteoporotic Origin. (EXPAND-US)
A Prospective, Multicenter, Post-Market Clinical Study Collecting Real-World Data of the VCFix Spinal System in Stand-Alone Configuration for Vertebral Augmentation (EXPAND-US)
This study is designed as a prospective, post-market, multi-center, single-arm study to collect real-world data of the VCFix Spinal System used in US clinical practice.
Approximately 5 centers in the US will enroll subjects with VCF in a non-randomized fashion, and VCFix will be used within its cleared purpose and indications for use.
The study has been designed to be methodologically compatible with the EU EXPAND (CIP-VS02-EU) study, thereby aiming for the pooling of data to the EU study. Data pooling will be pursued only as a sensitivity analysis if pre-specified similarity criteria are met. The US study provides meaningful real-world evidence regardless of pooling feasibility.
The targeted patient population, assessment schedule, and study endpoints are therefore similar to those of the EU EXPAND study.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Type d'étude
Inscription (Estimé)
Contacts et emplacements
Coordonnées de l'étude
- Nom: Clinical Research Manager
- Numéro de téléphone: +31 15 200 2151
- E-mail: expand-US@amberimplants.com
Lieux d'étude
-
-
New York
-
New York, New York, États-Unis, 10467
- Recrutement
- Montefiore Medical Center
-
Contact:
- Research Administrator
- Numéro de téléphone: (718) 920-6202
-
-
Oklahoma
-
Oklahoma City, Oklahoma, États-Unis, 73104
- Pas encore de recrutement
- University of Oklahoma Health Campus
-
Contact:
- Research Project Manager
- Numéro de téléphone: (405) 271-8001
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, États-Unis, 19107
- Pas encore de recrutement
- Rothman Orthopaedics
-
Contact:
- Clinical Research Coordinator
- Numéro de téléphone: (484) 335-2910
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
Méthode d'échantillonnage
Population étudiée
Adult patients undergoing treatment with the VCFix Spinal System as part of standard clinical care for vertebral compression fractures. The study will enroll patients treated according to routine clinical practice and will collect real-world evidence on clinical outcomes, radiographic outcomes, and patient-reported outcomes following treatment.
La description
Inclusion Criteria:
- 1. Subject is ≥ 21 to ≤ 85 years old. 2.
Single vertebral fracture which meets all of the following criteria:
- Type A fractures from AO spine classification (compression injuries);
- Vertebral fracture located in the thoracic and lumbar regions of the spine
- Fracture age < 6 weeks or fractures with anatomic signs of reducibility (based on radiographic evidence as well as patient history)
- Vertebral fracture shows an estimated height loss in the anterior or mid third of the vertebral body (VB) of at least 10% but not more than 60% based on radiographic evidence
- Target VB has appropriate anatomy, i.e. suitable pedicle diameter, pedicle length and chord length that would allow for selection of correct implant size, as described in the IFU and based on axial MRI/CT scan before surgery 3. Subject is diagnosed with, or has a suspected diagnosis of, severe osteoporosis, including low trabecular bone quality , and/or an oversized vertebral body as compared to implant size (e.g. relatively small pedicle requiring smaller implant size than desired for vertebral body size and/or fracture characteristics and location) 4. Subject has a NPRS back pain score of ≥5 5. Subject is a candidate for surgical intervention based on investigator opinion 6. Subject has a body Mass Index (BMI) < 35 7. Subject is mentally capable of complying with trial protocol requirements for the duration of the study 8. Subject can understand the risks and benefits of participating in the study and is able to provide written informed consent
Exclusion Criteria:
-
Neoplasms with posterior involvement and/or presence of a mass within the spinal canal
-
Non-mobile fractures (i.e., fracture is not recent (>6 weeks), bone marrow edema or fluid or empty cleft are not visible in radiographic imaging, or fracture mode does not allow for fracture reduction in craniocaudal direction).
-
Spondylolisthesis > Grade 1 at target vertebral body(s)
-
Local kyphotic angle > 30°
-
Any pre-existing vertebral fracture prior to the index fracture
-
Previous spine surgery, balloon kyphoplasty or vertebroplasty, for any vertebral fracture
-
Subjects that require anterior stabilization of the index fracture
-
Fracture to the pedicle based on radiographic evaluation
-
Spinal cord compression or canal compromise requiring decompression
-
Severe back pain due to causes other than acute fracture with NPRS score > 5
-
The subject has pain based on clinical diagnosis of herniated nucleus pulposus or severe spinal stenosis (progressive weakness or paralysis)
-
Pain due to any other condition that requires daily narcotic (opiates or opioids) medication
-
Pre-existing neurological deficit, radiculopathy or myelopathy
-
Pre-existing condition or significant co-morbidity:
- Uncontrolled diabetes (HbA1c >8%)
- Severe cardiopulmonary deficiencies
- Any other condition that would impact study outcome in the opinion of the investigator
-
Irreversible coagulopathy or bleeding disorder
-
Contraindications to both MRI and Computed Tomography (CT) imaging
-
Concurrent participation in another clinical study which could potentially interfere with the outcome of this study
-
A life expectancy less than the study duration or undergoing palliative care
-
Subject non-ambulatory prior to fracture Allergy to any components of the device/instruments used during the procedure
-
Allergy to any components of the device/instruments used during the procedure
-
Active or incompletely treated infection of the vertebral column or active systemic infection, including unresolved urinary tract infection
-
Any underlying systemic bone disease other than osteoporosis (e.g., osteomalacia, osteogenesis imperfecta, Paget's disease, etc.)
-
Any evidence of alcohol or drug abuse
-
Ongoing long-term steroid therapy (steroid dose ≥30 mg /day for >3 months)
-
The subject is currently on anti-cancer therapy or anti-HIV therapy
-
Pregnancy or subjects with child-bearing potential that are unwilling to use contraception throughout the study duration.
-
Patient known to be involved in medical litigation including Workmen's Compensation prior to the surgery
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Modèles d'observation: COHORT
- Perspectives temporelles: PROSPECTIVE
Cohortes et interventions
Groupe / Cohorte |
Intervention / Traitement |
|---|---|
|
Implant of the VCFix device per IFU
Patients with a (suspected) diagnosis of severe osteoporosis and a single vertebral compression fracture |
The distinguishing features of this inetrvention reside in: 1. In situ adjustment and maintenance of the height and angle of the device that allows expansion of the fractured VB in the cranio-caudal direction to realign the vertebral endplates and correct kyphosis. 2. The complex titanium perforated structure with optimized surface roughness that allows possible bone attachment, thereby permitting natural healing of the bone and potentially providing more stability to the device and the treated vertebra over time. 3. The ability to connect the posterior to the anterior column of the spine through the pedicle screw component of the VCFix implant, therefore improving the biomechanical load distribution and consequently the ability to stabilize more severe fractures. |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Incidence of serious adverse events (SAEs) related to the device and/or investigational procedure (safety)
Délai: 1 month
|
Incidence of serious adverse events (SAEs) related to the device and/or investigational procedure within 30 days post-procedure. This includes SAEs resulting from mechanical malfunction, structural compromise, device failure, or loss of intended function, as well as events representing deviations from the device's intended medical purpose. |
1 month
|
|
Vertebral fracture-related pain as assessed by the Numeric Pain Rating Scale (NPRS)
Délai: 6 months
|
Difference in vertebral fracture-related pain from baseline 6 months post procedure measured by the 11-point (0 = no pain, 10 is worst pain) Numerical Pain Rating Scale (NPRS). |
6 months
|
|
Functional disability, measured by the Oswestry disability index (ODI)
Délai: 6 months
|
Difference in functional disability, measured by the Oswestry disability index (ODI) (0-100 scale, where 0 is no disability and 100 is bed bound), from baseline to 6 months post procedure. |
6 months
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Vertebral height difference (anterior, midline, and posterior aspects)
Délai: Post-Operative, 1Month FU, 6 Months FU, 12 Months FU
|
Vertebral height difference (anterior, midline, and posterior aspects) at PO (Post-OP), 1M FU, 6M FU and 12M FU as compared to baseline. |
Post-Operative, 1Month FU, 6 Months FU, 12 Months FU
|
|
Kyphotic angle and Cobb angle improvement at Post-Operative, 1 Month FU, 6 Months FU and 12 Months FU.
Délai: Post-Operative, 1 Month FU, 6 Months FU and 12 Months FU.
|
Kyphotic angle and Cobb angle improvement |
Post-Operative, 1 Month FU, 6 Months FU and 12 Months FU.
|
|
Vertebral fracture-related pain as assessed by the Numeric Pain Rating Scale (NPRS)
Délai: Discharge, 1, 3, 6 and 12 Months FU compared to baseline.
|
Difference in vertebral fracture-related pain from baseline to Discharge, 1, 3, 6 and 12 Months post procedure measured by the 11-point (0 = no pain, 10 is worst pain) Numerical Pain Rating Scale (NPRS). |
Discharge, 1, 3, 6 and 12 Months FU compared to baseline.
|
|
Functional disability, measured by the Oswestry disability index (ODI)
Délai: Discharge, 1, 3, 6 and 12 months FU
|
Improvement in function (measured by the 100-point Oswestry Disability Index (ODI)) at discharge, 1, 3, 6 and 12 months FU compared to baseline. |
Discharge, 1, 3, 6 and 12 months FU
|
|
Health-related quality of life (HRQoL) measured by EuroQol 5-Dimension Scale (EQ-5D-5L) at 1 Month, 3 Months, 6 Months and 12 Months post-procedure compared to baseline
Délai: 1 Month, 3 Months, 6 Months and 12 Months post-procedure compared to baseline
|
Improvement of Health-related quality of life (HRQoL) |
1 Month, 3 Months, 6 Months and 12 Months post-procedure compared to baseline
|
|
Device-related serious adverse events assessed at 12- and 24- months post-procedure.
Délai: 12 months FU, 24 months FU
|
Device-related serious adverse events |
12 months FU, 24 months FU
|
|
All (per protocol reportable) adverse events assessed at 12- and 24- months post-procedure.
Délai: 12 Months FU, 24 Months FU
|
All (per protocol reportable) adverse events assessed at 12- and 24- months post-procedure. |
12 Months FU, 24 Months FU
|
Collaborateurs et enquêteurs
Parrainer
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- CIP-VS03-US
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
produit fabriqué et exporté des États-Unis.
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .